Journal of Controlled Release, Год журнала: 2024, Номер 371, С. 273 - 287
Опубликована: Июнь 1, 2024
Язык: Английский
ACS Nano, Год журнала: 2023, Номер 17(21), С. 20825 - 20849
Опубликована: Ноя. 3, 2023
Understanding the in vivo transport of nanoparticles provides guidelines for designing nanomedicines with higher efficacy and fewer side effects. Among many factors, size plays a key role controlling their behaviors due to existence various physiological thresholds within body size-dependent nano-bio interactions. Encouraged by evolving discoveries nanoparticle-size-dependent biological effects, we believe that it is necessary systematically summarize size-scaling laws nanoparticle vivo. In this review, summarized effect on along journey body: begin administration via different delivery routes, followed targeting intended tissues including tumors other organs, eventually clearance through liver or kidneys. We outlined tools investigating as well. Finally, discussed how may leverage tackle some challenges nanomedicine translation also raised important size-related questions remain be answered future.
Язык: Английский
Процитировано
220
Advanced Materials, Год журнала: 2021, Номер 33(31)
Опубликована: Май 28, 2021
Abstract Immunotherapy that can activate immunity or enhance the immunogenicity of tumors has emerged as one most effective methods for cancer therapy. Nevertheless, single‐mode immunotherapy is still confronted with several critical challenges, such low immune response, tumor infiltration, and complex immunosuppression microenvironment. Recently, combination other therapeutic modalities a powerful strategy to augment outcome in fighting against cancer. In this review, recent research advances chemotherapy, phototherapy, radiotherapy, sonodynamic therapy, metabolic microwave thermotherapy are summarized. Critical challenges future direction immunotherapy‐based also discussed.
Язык: Английский
Процитировано
167
Advanced Drug Delivery Reviews, Год журнала: 2021, Номер 179, С. 113914 - 113914
Опубликована: Авг. 4, 2021
Язык: Английский
Процитировано
125
Advanced Materials, Год журнала: 2022, Номер 35(10)
Опубликована: Дек. 28, 2022
The critical challenge for cancer vaccine-induced T-cell immunity is the sustained activation of antigen cross-presentation in antigen-presenting cells (APCs) with innate immune stimulation. In this study, it first discovered that clinically used magnetic contrast agents, iron oxide nanoparticles (IONPs), markedly augment type-I interferon (IFN-I) production profile stimulator genes (STING) agonist MSA-2 and achieve a 16-fold dosage-sparing effect human STING haplotype. Acid-ionizable copolymers are coassembled IONPs into nanoadjuvants to concentrate draining lymph nodes. top candidate nanoadjuvant (PEIM) efficiently delivers model ovalbumin (OVA) CD169+ APCs facilitates elicit 55-fold greater frequency antigen-specific CD8+ cytotoxic T-lymphocyte response than soluble antigen. PEIM@OVA nanovaccine immunization induces potent durable antitumor prevent tumor lung metastasis eliminate established tumors. Moreover, PEIM applicable deliver autologous synergizes checkpoint blockade therapy prevention postoperative recurrence distant B16-OVA melanoma MC38 colorectal models. acid-ionizable offers generalizable readily translatable strategy cascade personalized vaccination immunotherapy.
Язык: Английский
Процитировано
77
Nano-Micro Letters, Год журнала: 2023, Номер 15(1)
Опубликована: Июнь 3, 2023
Abstract Immunotherapy has become a promising research “hotspot” in cancer treatment. “Soldier” immune cells are not uniform throughout the body; they accumulate mostly organs such as spleen and lymph nodes (LNs), etc. The unique structure of LNs provides microenvironment suitable for survival, activation, proliferation multiple types cells. play an important role both initiation adaptive immunity generation durable anti-tumor responses. Antigens taken up by antigen-presenting peripheral tissues need to migrate with lymphatic fluid activate lymphocytes therein. Meanwhile, accumulation retaining many functional compounds enhance their efficacy significantly. Therefore, have key target tumor immunotherapy. Unfortunately, nonspecific distribution drugs vivo greatly limits activation cells, which leads unsatisfactory effects. efficient nano-delivery system is effective strategy maximize drugs. Nano-delivery systems shown beneficial improving biodistribution enhancing lymphoid tissues, exhibiting powerful prospects achieving delivery LNs. Herein, physiological barriers were summarized factors affecting discussed thoroughly. Moreover, developments reviewed transformation targeting nanocarriers discussed.
Язык: Английский
Процитировано
61
Chemical Society Reviews, Год журнала: 2023, Номер 52(9), С. 2886 - 2910
Опубликована: Янв. 1, 2023
Cancer vaccines have emerged as a powerful new tool for cancer immunotherapy. Adjuvants are vaccine ingredients that enhance the strength, velocity, and duration of immune response. The success adjuvants in achieving stable, safe, immunogenic has generated enthusiasm adjuvant development. Specifically, advances materials science providing insights into rational design topical Here, we outline current state engineering strategies, including those based on molecular adjuvants, polymers/lipids, inorganic nanoparticles, bio-derived materials, We also elaborate how these strategies physicochemical features involved influence effects adjuvants.
Язык: Английский
Процитировано
59
Small, Год журнала: 2024, Номер 20(35)
Опубликована: Май 1, 2024
Abstract Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art nanovaccine development, elucidating innovative strategies and technologies employed their design. It explores both preclinical clinical advancements, emphasizing key studies demonstrating potential elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, impact of nanoscale properties on performance. Detailed insights into complex interplay between tumor microenvironment responses are provided, highlighting challenges opportunities optimizing therapeutic outcomes. Additionally, presents thorough analysis ongoing trials, presenting snapshot landscape. By curating latest scientific findings developments, this aims serve as comprehensive resource researchers clinicians engaged advancing immunotherapy. Integrating design holds immense promise revolutionizing treatment paradigms, provides timely update evolving landscape nanovaccines.
Язык: Английский
Процитировано
24
Small, Год журнала: 2024, Номер 20(19)
Опубликована: Фев. 7, 2024
Abstract Immunotherapy has emerged as a potent strategy in cancer treatment, with many approved drugs and modalities the development stages. Despite its promise, immunotherapy is not without limitations, including side effects suboptimal efficacy. Using nanoparticles (NPs) delivery vehicles to target lymph nodes (LNs) can improve efficacy of reduce patients. In this context, paper reviews LN‐targeted immunotherapeutic NP strategies, mechanisms transport during LN targeting, their related biosafety risks. targeting LNs involves either passive influenced by physical properties, or active facilitated affinity ligands on surfaces, while alternative methods, such intranodal injection high endothelial venule (HEV) have uncertain clinical applicability require further research validation. NPs for increase biocompatibility, but risks toxicity, organ accumulation, oxidative stress remain, although strategies biodegradable biomacromolecules, polyethylene glycol (PEG) coating, impurity addition mitigate these Additionally, work concludes future‐oriented discussion, offering critical insights into field.
Язык: Английский
Процитировано
23
Advanced Drug Delivery Reviews, Год журнала: 2024, Номер 209, С. 115304 - 115304
Опубликована: Апрель 9, 2024
Язык: Английский
Процитировано
20
Nano-Micro Letters, Год журнала: 2021, Номер 13(1)
Опубликована: Март 16, 2021
Abstract Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs) have been reported with a high clinical success rate, numerous patients still bear ‘cold’ tumors insufficient T cell infiltration and low immunogenicity, responding poorly to ICI therapy. Considering the advancements in precision medicine, in-depth mechanism studies on tumor microenvironment (TIME) among cold are required improve treatment for these patients. Nanomedicine has emerged as promising drug delivery system immunotherapy, activates function, modulates TIME, applied combination other therapeutic strategies. This review initially summarizes mechanisms underlying immunosuppressive TIME addresses recent nanotechnology reversal-based therapies, well brief talk about feasibility of translation.
Язык: Английский
Процитировано
77